REVIEW article
Front. Bioeng. Biotechnol.
Sec. Tissue Engineering and Regenerative Medicine
Volume 13 - 2025 | doi: 10.3389/fbioe.2025.1590393
Advances in human Amniotic Placenta Membrane-Derived Mesenchymal Stromal Cells (hAMSCs) for Regenerative Medicine: Enhancing Therapeutic Potential with Biomaterials and Scaffolds
Provisionally accepted
- Facultad de C.C. Experimentales, Universidad Francisco de Vitoria, Madrid, Spain
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Mesenchymal stromal cells (MSCs) derived from the human placenta amniotic membrane (hAMSCs) have emerged as a promising option in regenerative therapies due to their multipotent differentiation and tissue regeneration capacity, low immunogenicity, and potent immunomodulatory properties. Compared to MSCs from other sources, such as bone marrow or adipose tissue, hAMSCs offer significant advantages, including higher proliferation, lower risk of immune rejection, and greater availability, as their collection is non-invasive and free of ethical concerns. These characteristics make them ideal candidates for regenerative medicine applications and the treatment of degenerative diseases. In this work, we review, from a preclinical perspective, the properties and therapeutic characteristics of hAMSCs derived from the human placenta, and the enhancement in their therapeutic properties when applied in combination with biomaterials such as natural and synthetic polymers or scaffolds, for the treatment of different disorders. The combination of hAMSCs with biomaterials and scaffolds provides a more efficient approach to tissue engineering, enhancing cell viability, proliferation, and integration into damaged tissues. Furthermore, we discuss the properties of scaffolds used to enhance the regenerative capacity of these cells, focusing on their biocompatibility, biodegradability, and ability to mimic the native extracellular matrix. This combined approach has the potential to revolutionize regenerative medicine, providing more effective and personalized therapies for a wide range of chronic and debilitating diseases.
Keywords: placenta-stromal-cells, Biomaterials, Regenerative-medicine, cell-therapy, Scaffold
Received: 09 Mar 2025; Accepted: 01 Sep 2025.
Copyright: © 2025 de Laorden, Rodilla, Arroyo-Hernández and Iglesias. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Maite Iglesias, Facultad de C.C. Experimentales, Universidad Francisco de Vitoria, Madrid, Spain
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.